Next-Generation High-Performance Immunoassays: Transforming Disease Diagnosis

Key Advancements in Immunoassay Technology
The latest issue of Nature Focal Point on Medical Technology in Japan explores Japan’s development of new technologies in the medical care field such as robots for hospitals, blood tests for depression and Alzheimer’s disease, and more.
High-performance immunoassay technologies are set to revolutionize the diagnosis and treatment of various diseases and health conditions. Immunoassays, which leverage specific reactions between antibodies and antigens, are invaluable in medical diagnostics and drug discovery. Fujirebio, a Tokyo-based company, is at the forefront of developing these advanced systems.

Impact on Early Disease Detection and Diagnosis
Fujirebio’s Lumipulse system, one of the first fully automated chemiluminescent enzyme immunoassay (CLEIA) instruments, exemplifies their innovation. Their latest advancement, iTACT (Immunoassay for Total Antigen including Complex via pretreatment), enhances the sensitivity and specificity of immunoassays by incorporating a pretreatment stage to break down antigen complexes and inactivate interfering substances.

These advancements are crucial for making the diagnosis of cancers, neurodegenerative disorders, infectious diseases, and other conditions as simple and precise as possible. View the full article here.

Reaching our Life & Physical sciences audiences

Take advantage of our life sciences and physical sciences advertising and content solutions to get your message in front of thousands of scientists reading our 1,600 science journals. Discover our scientist audiences >>